Femasys (FEMY) Income from Continuing Operations (2020 - 2025)
Femasys' (FEMY) quarterly Income from Continuing Operations came in at 4585922.0 in Q2 2025, up 2.11% YoY from 4491339.31 in Q2 2024, and up 22.23% on a QoQ basis from 5896839.0 in Q1 2025.
Femasys (FEMY) Income from Continuing Operations (2020 - 2025) Analysis & Trends
Femasys (FEMY) has 6 years of Income from Continuing Operations data on file, last reported at 4585922.0 in Q2 2025.
- Quarterly Income from Continuing Operations rose 2.11% year-over-year to 4585922.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was 21015305.0 (down 25.9% YoY) and the FY2025 annual result came in at 18627615.0, up 1.0% from the prior year.
- Income from Continuing Operations improved to 4585922.0 in Q2 2025, from 5896839.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1083059.0 in Q2 2021 to a low of 5896839.0 in Q1 2025.
- A 5-year average of 3498632.44 and a median of 3052943.5 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations advanced 27.09% — and 2022, when it sank 162.38%.
- Tracing FEMY's Income from Continuing Operations over 5 years: stood at 2364853.0 in 2021, then retreated by 27.04% to 3004204.0 in 2022, then slumped by 46.81% to 4410454.0 in 2023, then dropped by 16.17% to 5123684.0 in 2024, then grew by 10.5% to 4585922.0 in 2025.
- The last three Income from Continuing Operations figures came in at 4585922.0 (Q2 2025), 5896839.0 (Q1 2025), and 5123684.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | 452.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | 135.00 Mn |
| 10 | Femasys | 9.97 Mn | 8.53 Mn | 189,391.00 | -4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4.59 Mn |
| Mar 31, 2025 | -5.90 Mn |
| Dec 31, 2024 | -5.12 Mn |
| Sep 30, 2024 | -5.41 Mn |
| Jun 30, 2024 | -4.68 Mn |
| Mar 31, 2024 | -3.60 Mn |
| Dec 31, 2023 | -4.41 Mn |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -2.89 Mn |
| Mar 31, 2023 | -3.04 Mn |
| Dec 31, 2022 | -3.00 Mn |
| Sep 30, 2022 | -3.06 Mn |
| Jun 30, 2022 | -2.84 Mn |
| Mar 31, 2022 | -2.89 Mn |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | -2.26 Mn |
| Jun 30, 2021 | -1.08 Mn |
| Mar 31, 2021 | -1.83 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.57 Mn |